Combined treatment with anti-Sema4D antibodies and immune checkpoint inhibitors enhances the recruitment of effector lymphocytes and antigen-presenting cells while reducing immunosuppressive populations, leading to effective TME remodeling and tumor rejection [192]. Here, SEMA4D is linked to neoplasm.